RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics, which were pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #ScienceCurious to learn more about #RNAi? Click here: https://bit.ly/3oR8r2l #RNAiTherapeutics #siRNA #GeneSilencing #RNA
Alnylam Pharmaceuticals
Biotechnology Research
Cambridge, Massachusetts 200,805 followers
Alnylam is the leading RNAi therapeutics company. We're a fast-growing biopharma with a deep pipeline and global reach.
About us
ALNYLAM IS LEADING THE RNAi REVOLUTION™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, four more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,500+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-23), Science Magazine (2018-23), Fast Company (Best Workplaces for Innovators 2020-23) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861
- Website
-
http://www.alnylam.com
External link for Alnylam Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2002
- Specialties
- Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, and RNAi
Locations
Employees at Alnylam Pharmaceuticals
Updates
-
As a pioneer in RNA-based therapeutics, we relish the opportunity to engage with peers and discuss what's new and next in nucleic acid medicines. If you do too, join us and co-organizers Nature Biotechnology, Ionis Pharmaceuticals, Inc. and UC San Diego School of Medicine at the #RNAbench2bedside conference happening Dec 9-11. Learn more: https://lnkd.in/e5DmnhGA and submit an abstract through Oct 9: https://bit.ly/3WJddzQ #RNA #RNAi #RNAinterference #RNAiTherapeutics #siRNA
-
We’re harnessing the potential of RNA interference (RNAi) and will be presenting new data at the European Society of Cardiology Congress 2024 8/30-9/2 in London. Learn more: https://bit.ly/3X4wxZL
-
Happy #RNAday! RNA is truly A-mazing. It’s responsible for many things but primary among them is facilitating protein synthesis - the process by which your body makes new proteins, which are the "workers" in the biochemistry of life. But sometimes, faulty proteins, or too much of a protein, can cause or contribute to disease. Fortunately, a type of RNA can be used to treat disease! RNA interference (RNAi) therapeutics utilize small interfering RNA (siRNA) to prevent the production of these unwanted proteins. Watch this video to learn how. #ScienceCurious to learn even more? Click here: https://bit.ly/3oR8r2l #RNA #RNAi #RNAinterference #RNAiTherapeutics #siRNA #science
-
We've reported Q2 2024 financial results and highlights of recent period activity. Join us LIVE TODAY at 8:30 AM ET to hear from our leadership and/or access the replay later today at: https://bit.ly/374c75E. Read the Q2 2024 financial results press release: https://bit.ly/4dpnec6 #RNAi #RNAiTherapeutics #siRNA
-
We'll be sharing 2nd Quarter 2024 financial results this Thursday, 8/1 at 8:30 AM ET, during a LIVE webcast. Register here: https://bit.ly/374c75E and access the replay at the same link later in the day. #RNAi #RNAitherapeutics #siRNA
-
It's #NationalInternDay and we're celebrating the contributions of our #interns who represent the incredible potential of the next generation of #biopharma professionals! We believe that the seeds of tomorrow's breakthroughs are planted today through inclusive programs that provide opportunities to early career individuals from diverse backgrounds, including those who come to us from our partner Project Onramp. You can learn more about our Internship program here: https://bit.ly/3W6LHM8
-
Innovative science is only part of the equation when it comes to developing new medicines. Clinical research relies on partnerships with health care professionals and patient advocates but most importantly, the people who choose to participate in #ClinicalTrials. Learn more about Alnylam's clinical trials: https://bit.ly/35jLcrU
-
Alnylam's corporate responsibility efforts are driven by the passion of our employees to make a positive impact on the world beyond the medicines we make. Whether it's at work or in communities across the globe, their dedication to doing good is evident every day. Our 2023 Corporate Responsibility Report details our work, shares our progress, reflects our commitment to accountability, and looks ahead to what we aim to accomplish in the years to come. Learn more and download the report: https://bit.ly/3UoMUO2 #ESG #CorporateResponsibility #CSR
-
+1
-
Earning a spot on Fortune's Best Workplace for Millennials list two years in a row? That's something to be #AlnylamProud of! We know our success and ability to deliver innovative new medicines to patients is made possible by the strength of our culture and the important contribution of all of our employees, including our millennial colleagues! Learn more and see the list: https://bit.ly/4d71TDQ. #CompanyCulture #GreatPlaceToWork #BestWorkplaces Great Place To Work US
Similar pages
Browse jobs
Stock
ALNY
NASDAQ
20 minutes delay
$271.98
2.46 (0.913%)
- Open
- 269.52
- Low
- 267.622
- High
- 274
Data from Refinitiv
See more info on